Bundled care for septic shock : an analysis of clinical trials
CONTEXT: Sepsis bundles have been developed to improve patient outcomes by combining component therapies. Valid bundles require effective components with additive benefits. Proponents encourage evaluation of bundles, both as a whole and based on the performance of each component.
OBJECTIVE: Assess the association between outcome and the utilization of component therapies in studies of sepsis bundles.
DATA SOURCE: Database searches (January 1980 to July 2008) of PubMed, Embase, and the Cochrane Library, using the terms sepsis, bundles, guidelines, and early goal directed therapy.
DATA EXTRACTION: Inclusion required comparison of septic adults who received bundled care vs. nonprotocolized care. Survival and use rates for individual interventions were abstracted.
MAIN RESULTS: Eight unblinded trials, one randomized and seven with historical controls, were identified. Sepsis bundles were associated with a consistent (I2 = 0%, p = .87) and significant increase in survival (odds ratio, 1.91; 95% confidence interval, 1.49-2.45; p < .0001). For all studies reporting such data, there were consistent (I2 = 0%, p > or = .64) decreases in time to antibiotics, and increases in the appropriateness of antibiotics (p < or = .0002 for both). In contrast, significant heterogeneity was seen across trials for all other treatments (antibiotic use within a specified time period; administration of fluids, vasopressors, inotropes, and packed red blood cells titrated to hemodynamic goals; corticosteroids and human recombinant activated protein C use) (all I2 > or = 67%, p < .002). Except for antibiotics, sepsis bundle components are still being investigated for efficacy in randomized controlled trials.
CONCLUSION: Bundle use was associated with consistent and significant improvement in survival and antibiotic use. Use of other bundle components changed heterogeneously across studies, making their impact on survival uncertain. However, this analysis should be interpreted cautiously as these studies were unblinded, and only one was randomized.
| Errataetall: |
CommentIn: Crit Care Med. 2010 Feb;38(2):733-4. - PMID 20083953 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Critical care medicine - 38(2010), 2 vom: 27. Feb., Seite 668-78 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barochia, Amisha V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 22.02.2010 Date Revised 08.04.2022 published: Print CommentIn: Crit Care Med. 2010 Feb;38(2):733-4. - PMID 20083953 Citation Status MEDLINE |
|---|
| doi: |
10.1097/CCM.0b013e3181cb0ddf |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM193934116 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM193934116 | ||
| 003 | DE-627 | ||
| 005 | 20231223195708.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CCM.0b013e3181cb0ddf |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0646.xml |
| 035 | |a (DE-627)NLM193934116 | ||
| 035 | |a (NLM)20029343 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barochia, Amisha V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bundled care for septic shock |b an analysis of clinical trials |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2010 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Crit Care Med. 2010 Feb;38(2):733-4. - PMID 20083953 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a CONTEXT: Sepsis bundles have been developed to improve patient outcomes by combining component therapies. Valid bundles require effective components with additive benefits. Proponents encourage evaluation of bundles, both as a whole and based on the performance of each component | ||
| 520 | |a OBJECTIVE: Assess the association between outcome and the utilization of component therapies in studies of sepsis bundles | ||
| 520 | |a DATA SOURCE: Database searches (January 1980 to July 2008) of PubMed, Embase, and the Cochrane Library, using the terms sepsis, bundles, guidelines, and early goal directed therapy | ||
| 520 | |a DATA EXTRACTION: Inclusion required comparison of septic adults who received bundled care vs. nonprotocolized care. Survival and use rates for individual interventions were abstracted | ||
| 520 | |a MAIN RESULTS: Eight unblinded trials, one randomized and seven with historical controls, were identified. Sepsis bundles were associated with a consistent (I2 = 0%, p = .87) and significant increase in survival (odds ratio, 1.91; 95% confidence interval, 1.49-2.45; p < .0001). For all studies reporting such data, there were consistent (I2 = 0%, p > or = .64) decreases in time to antibiotics, and increases in the appropriateness of antibiotics (p < or = .0002 for both). In contrast, significant heterogeneity was seen across trials for all other treatments (antibiotic use within a specified time period; administration of fluids, vasopressors, inotropes, and packed red blood cells titrated to hemodynamic goals; corticosteroids and human recombinant activated protein C use) (all I2 > or = 67%, p < .002). Except for antibiotics, sepsis bundle components are still being investigated for efficacy in randomized controlled trials | ||
| 520 | |a CONCLUSION: Bundle use was associated with consistent and significant improvement in survival and antibiotic use. Use of other bundle components changed heterogeneously across studies, making their impact on survival uncertain. However, this analysis should be interpreted cautiously as these studies were unblinded, and only one was randomized | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Cui, Xizhong |e verfasserin |4 aut | |
| 700 | 1 | |a Vitberg, David |e verfasserin |4 aut | |
| 700 | 1 | |a Suffredini, Anthony F |e verfasserin |4 aut | |
| 700 | 1 | |a O'Grady, Naomi P |e verfasserin |4 aut | |
| 700 | 1 | |a Banks, Steven M |e verfasserin |4 aut | |
| 700 | 1 | |a Minneci, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Kern, Steven J |e verfasserin |4 aut | |
| 700 | 1 | |a Danner, Robert L |e verfasserin |4 aut | |
| 700 | 1 | |a Natanson, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Eichacker, Peter Q |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical care medicine |d 1973 |g 38(2010), 2 vom: 27. Feb., Seite 668-78 |w (DE-627)NLM000002631 |x 1530-0293 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2010 |g number:2 |g day:27 |g month:02 |g pages:668-78 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CCM.0b013e3181cb0ddf |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2010 |e 2 |b 27 |c 02 |h 668-78 | ||